MedTrace Logo

The Postoperative Lidocaine and Ketamine Effects on Morphine Requirement in Bariatric Surgery

NCT05591105 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2024-07-03

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the quality of postoperative analgesia in a group of obese patients schedule to bariatric surgery under TIVA Opiod-free after to receive lidocaine and ketamine perfusion. The main question it aims to answer are: How lidocaine and ketamine perfusion during recovery period does impact over morphine consumption on the following 48 hours after surgery? All participants will receive total intravenous anesthesia and, at the end of the surgery, they will be divided in two groups, group A: placebo and, group B: with postoperative lidocaine and ketamine perfusion. Our hypothesis is ketamine and lidocaine are a good alternative to decrease the use of morphine in obese patients.

Conditions

  • Pharmacological Action
  • Post Operative Pain
  • Opioid Use
  • Obesity, Morbid
  • Anesthesia Morbidity

Interventions

DRUG

Control Group

At the end of surgery, they will continue receiving analgesia according the schedule and, addicionally, lidocaine (1 mg/kg/h) and Ketamine (0,15 mg/kg/h) for 90 minute as part of postoperative analgesia.

DRUG

Placebo

At the end of surgery, they will continue receiving analgesia according the schedule.

Sponsors & Collaborators

  • Tiva Group

    lead OTHER

Principal Investigators

  • Carolina Frederico · Tivagrooup

  • Gregory Contreras-Pérez · Tiva Group

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-15
Primary Completion
2023-12-30
Completion
2024-01-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05591105 on ClinicalTrials.gov